ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
ProQR Therapeutics N.V. (PRQR) is a Biotechnology company based in NL with a market capitalization of $198M. Revenue declined 19.2% year-over-year and free cash flow was negative at -$59.1M. This page tracks PRQR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
NL · 166 employees · IPO Sep 18, 2014
Valuation
Valuation & price
$1.59as of May 17, 2026· -47.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
4.01
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$198M
Market cap
-19.2%
Revenue growth (YoY)
83.0%
Gross margin
-$59.1M
Free cash flow (USD)
-$78.4M
Net debt
Net cash position
29.0%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
3
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed Jun 2, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 21, 2026Filing
Insider Buy $258KFilius Bart · Director · $257.9K
- Insider buyJul 13, 2026Filing
Insider Buy $261Kde Boer Daniel Anton · Director, Chief Executive Officer · $261K
- Insider buyJul 8, 2026Filing
Insider Buy $238Kde Boer Daniel Anton · Director, Chief Executive Officer · $238.5K
- 6-K filingJun 25, 2026Filing
Positive Phase 1 Data
- 6-K filingJun 25, 2026Filing
Underwriting Agreement
- Annual reportJun 2, 2026Filing
Annual Report Filed
- Annual reportMay 12, 2026Filing
Annual Report Filed
- Annual reportMay 12, 2026Filing
Annual Report Filed
- 6-K filingMay 4, 2026Filing
2026 Annual General Meeting Agenda
- 6-K filingApr 30, 2026Filing
Management Change
Questions
Frequently asked questions
What is ProQR Therapeutics N.V.'s market cap?
ProQR Therapeutics N.V. (PRQR) has a market capitalization of $198M.
What is PRQR's P/E ratio?
A meaningful P/E ratio is not available for PRQR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PRQR's price-to-book (P/B) ratio?
PRQR trades at 4.01 times book value per share.
Are insiders buying PRQR stock?
Yes — SEC Form 4 filings show 3 open-market insider buys and 0 sells at ProQR Therapeutics N.V. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.